QUIRIN PRIVATBANK EQUITY RESEARCH

Similar documents
Reduced EPS but smart acquisition

Strong growth ahead QUIRIN PRIVATBANK EQUITY RESEARCH. 18 Mai 2017 EQS Group AG

Highest single order in paragon s history

The growth story continues

Leading Industrial IT set for growth

Aumann AG: The best of two worlds

Price Target: EUR (22.00)

Price Target: EUR (20.00) 04 April 2012 FY11 results: No surprises so far

Price Target: EUR 4.15 (3.80)

Solid preliminary FY 2014 results released. Net asset value increased by 3.5% in H 2014 with difficult trading environment

Price Target: EUR (20.60) 07 April 2011 Solid FY10 & More to come

Borussia Dortmund GmbH & Co. KGaA

Price Target: EUR (17.00)

Borussia Dortmund GmbH & Co. KGaA

Price Target: EUR 1.60 (1.50)

Borussia Dortmund GmbH & Co KGaA

Price Target: EUR 5.00 (5.00)

Financials/Prime Standard

Sandpiper Digital Payments AG

PrimeCity Investment Plc

Price Target: EUR 1.30 (1.30)

Buy PT EUR24,00, upside 23%

Borussia Dortmund GmbH & Co KGaA

Price Target: EUR (50.00)

EQUINET INVESTIGATOR

Leifheit AG. Management Meeting confirms our positive view. Buy (Buy) EUR (60.00 EUR ) BANKHAUS LAMPE // 1 16/02/2016

Price Target: EUR (35.00)

Research Note. Fair Value REIT-AG

Adler Real Estate AG. Fewer vacancies, more properties. Buy (Buy) EUR (16.50 EUR ) BANKHAUS LAMPE // 1 28/03/2017

Borussia Dortmund GmbH & Co. KGaA

Electronics Line 3000 Ltd.

Price target: EUR (20.00) 15 August 2014 Final 2Q figures match preliminary figures

BUY (previous: BUY) (previous: 77.50)

Net income (after min.) >100% EPS [ ] (0.63) (0.27) >100% 0.20 (1.85)

15/11/2017 GBC Research Comment Rock Tech Lithium Inc.

Q1 results strongly above estimates

PA Power Automation AG

NOT RATED. (previously Buy) (previously 1.73) adj. net (mln ) DPS ( ) adj. EPS ( )

adesso AG MAY 31, 2012

Klaus Kränzle, Please inform yourself of important disclosures and disclaimers in the appendix

Geratherm Medical AG Strong demand in Q3

CLERE AG DELISTING & TAKEOVER BID BY MAIN SHAREHOLDER. FIRST BERLIN Equity Research. Delisting & PRICE TARGET C L

Evaluation result Fair value DPS. adj. net. adj. EPS ( )

Buy PT 24,00, upside 23%

adesso AG November 5, 2012

MiFID II Research Rules Sellside Perspective

ISRA VISION Neutral

MATELAN Research. InVision 49.0 Buy. Excellent margin trend in Prelims. Update Note. 24 February Company / Sector Fair Value Recommendation

HOLD (previous: BUY) (previous: 68.00)

Very solid Q3; excellent story, but priced in; TP upped to 60.00; downgrade to neutral. Q3 2016: Very solid quarter, better than expected

HAEMATO AG SOLID UPTICK IN H2 SALES AND EBIT MARGIN. FIRST BERLIN Equity Research PRICE TARGET H A

5 September 2016 OTI Greentech AG. FIRST BERLIN Equity Research

Demand for sovereign bonds: The importance of diversity

adesso AG Germany - IT Services

Will the global economy weather the storm of protectionism?

1 November 2017 M1 Kliniken AG. FIRST BERLIN Equity Research. Update following

Bullion Weekly Technicals Tuesday, 24 November 2015

-for professional clients only-

BDI BioEnergy Internat Buy

adesso AG Germany - IT Services

HOLD 51,85. (previous: Hold) (previous: 51,65)

SFC Energy AG STRONG GROWTH AND PROFITABILITY AHEAD. FIRST BERLIN Equity Research. Preliminary PRICE TARGET S F

PA Power Automation AG

ad pepper media International N.V.

Borussia Dortmund GmbH & Co KGaA

Evaluation result Fair value BUY (prev.: BUY) (prev.: 21.52)

Tel.: +49 (0) Tel.: +49 (0)

Advanced Vision Techn Buy

BUY (previous: BUY) (previous: 3.70)

TEMPORARILY NO VALUATION. (previous: not rated)

Russian Ruble: Wethering global storms

ContextVision. Solid 2Q and more details on the contract awaited. August 18 th 2014 Share price: NOK Target: NOK Risk: Medium.

Intershop Communications AG

BaFin the integrated financial supervisor

Air France-KLM. Hold TP 6.50 CP 7.59 (Close 21 October 2013) Q3 due 31 October More restructuring needed. Equity Research Quick Bite Preview

Corporate Finance Terms of Business Terms Client DEFINITIONS Anti-Bribery and Corruption Law Applicable Law BaFin Bank Business Day Clearing System

18 October 2016 aventron AG. FIRST BERLIN Equity Research

ContextVision. Expecting solid results and awaiting progress update on research program

14 September 2017 Pharming Group NV. FIRST BERLIN Equity Research. Update. Bloomberg: PHARM NA Return Potential 216.5% ISIN: NL

HOLD (previous: Hold) (previous: 51.85)

TAV Airports EARNINGS REVIEW 4Q17. Bottom-line below consensus BUY TRY22.90

ContextVision. Neutral stance maintained after 3Q. 3Q14 Results analysis November 5 th 2014 Share price: NOK Target: NOK 24.

Flash Economics. Measured GDP and true GDP. 14 September

Vontobel Morning Note

20 April 2018 Energiekontor AG. FIRST BERLIN Equity Research

Information for Eligible Counterparties pursuant to the German Securities Trading Act (Wertpapierhandelsgesetz)

18 January 2018 Pharming Group NV. FIRST BERLIN Equity Research. Update. Bloomberg: PHARM NA Return Potential 45.9% ISIN: NL

- 2/7 - Segment Discussion August 05, Segment Discussion. Stock and Valuation

PNE WIND AG OFFSHORE PROJECT ATLANTIS I SOLD. FIRST BERLIN Equity Research. Good start to PRICE TARGET P N

13 May 2016 PNE WIND AG. FIRST BERLIN Equity Research

22 November 2017 Energiekontor AG. FIRST BERLIN Equity Research

18 November 2016 Energiekontor AG. FIRST BERLIN Equity Research

Bullion Weekly Technicals Monday, 15 October 2012

MPH Mittelstaendische Pharma Holding AG M P

Contracted through the bottom

Bullion Weekly Technicals Wednesday, 26 April 2017

27 March 2019 SFC Energy AG. FIRST BERLIN Equity Research. Final SUSTAINABLE MACRO TRENDS SUPPORT FUEL CELL BUSINESS

FinTech Group. Buy TP 38 (from 30) CP (Closing 3 May 2018) Ready for accelerated growth in Equity Research Quick Bite

Eckert & Ziegler AG Germany - High-tech Engineering

Bank Information of. IKB Deutsche Industriebank AG. with regard to the provision of investment services and ancillary investment services

Transcription:

RACE HORSE QUIRIN PRIVATBANK EQUITY RESEARCH 14 August 2017 EQS Group AG BUY (BUY) PT 60.00 (EUR 60.00) EQS: H1-17: Sales up by 45% yoy Bloomberg EQS GY Sector Technology Rating BUY (BUY) Target price EUR 60.00 Share price EUR 56.00 Market cap EUR 73.3m Strong sales growth in H1-17 The company generated revenues of EUR 15.01m in H1-17, representing a 45% increase over the same period last year. EBIT before acquisition costs, purchase price allocation and scheduled amortization of the acquired customer bases (non-ifrs) declined slightly by 3% to EUR 912 thousand. Adjusted Group net profit amounted to EUR -37 thousand. Adjusted earnings per share are EUR -0.03. Ariva major force behind growth The significant increase in revenues is mainly attributable to a rise in sales in Germany (+60% to EUR 11.85m), particularly the consolidated sales revenues of the majority stake in ARIVA.DE AG: Sales increased by over 30% or EUR 3.5m as companies prepare for the obligatory adoption of basic information sheets for financial products mandated by the PRIIP regulation. Full year guidance confirmed The Executive Board of EQS Group expects double-digit revenue growth in 2017, of between 20% and 25%, amounting to EUR 31.2m to EUR 32.5m. Adjusted EBIT is expected to increase by 10% to 20%, amounting to EUR 3.6m to EUR 3.9m. in particular Q4 delivers the major contribution to earnings. We therefore confirm BUY and the EUR 60.00 TP. Analyst Ralf Marinoni ralf.marinoni@quirinprivatbank.de T +49 (0)69 2475049 27 1

Legal Disclaimer This document has been prepared by Quirin Privat claim completeness regarding all the information on the stocks, stock markets or developments referred to in it. On no account should the document be regarded as a substitute for the recipient procuring information for himself/herself or exercising his/her own judgments. The document has been produced for information purposes for institutional clients or market professionals. Private customers, into whose possession this document comes, should discuss possible investment decisions with their customer service officer as differing views and opinions may exist with regard to the stocks referred to in this document. This document is not a solicitation or an offer to buy or sell the mentioned stock. The document may include certain descriptions, statements, estimates, and conclusions underlining potential market and company development. These reflect assumptions, which may turn out to be incorrect. The Bank and/or its employees accept no liability whatsoever for any direct or consequential loss or damages of any kind arising out of the use of this document or any part of its content. The Bank and/or its employees may hold, buy or sell positions in any securities mentioned in this document, derivatives thereon or related financial products. The Bank and/or its employees may underwrite issues for any securities mentioned in this document, derivatives thereon or related financial products or seek to perform capital market or underwriting services. The Bank reserves all the rights in this document. The preparation of this document is subject to regulation by German Law. Remarks regarding to U.K. clients: Distribution of this material in the U.K.is governed by the FSA Rules. This Report is intended only for distribution to Professional Clients or Eligible Counterparties (as defined under the rules of the FSA) and is not directed at Retail Clients (as defined under the rules of the FSA). Disclosures in respect of section 34b of the German Securities Trading Act and FinAnV Section 34b of the German Securities Trading Act in combination with the FinAnV requires an enterprise preparing a securities analyses to point possible conflicts of interest with respect to the company that is the subject of the analyses. Catalogue of potential conflicts of interest: 1. The Bank and/or its affiliate(s) own a net long or short position exceeding the threshold of 0,5% of the total issued share capital of the company that is the subject of the Research Document, calculated in accordance with Article 3 of regulation (EU) No 236/2012 and with Chapter III and IV of Commission Delegated Regulation (EU) No 918/20127 2. The company that is the subject of the Research Document owns 5% or more in the total issued share capital of the Bank and/or its affiliate(s) 3. The Bank and/or its affiliate(s) was Lead Manager or Co-Lead Manager over the previous 12 months of a public offering of analyzed company 4. The Bank and/or its affiliate(s) act as Market Maker or Designated Sponsor for the analyzed company 5. The Bank and/or its affiliate(s) over the previous 12 months has been providing investment banking services for the analyzed company for which a compensation has been or will be paid 6. The responsible analyst named in this report disclosed a draft of the analysis set forth in this Research Document to the company that is the subject of this Research Document for fact reviewing purposes and changes were made to this Research Document before publication 7. The Bank and/or its affiliate(s) effected an agreement with the analyzed company for the preparation of the financial analysis 8. The Bank and/or its affiliate(s) holds a trading position in shares of the analyzed company 9. The Bank and/or its affiliate(s) has other important financial interests in relation to the analyzed company In relation to the security or financial instrument discussed in this analyses the following possible conflict of interest exists: (-) The Bank have set up effective organizational administrative arrangements to prevent and avoid possible conflicts of interest and, where applicable, to disclose them. Monday, August 14, 2017 2

The valuation underlying the rating of the company analyzed in this report is based on generally accepted and widely used methods of fundamental valuation, such as the DCF model, Free Cash Flow Value Potential, peer group comparison and where applicable a sum-of-the-parts model. We do not commit ourselves in advance to whether and in which intervals an update is made. The document and the recommendation and the estimations contained therein are not linked whether directly or indirectly to the compensation of the analyst responsible for the document. All share prices given in this equity analysis are closing prices from the last trading day before the publication date stated, unless another point in time is explicitly stated. The rating in this report are based on the analyst s expectation of the absolute change in stock price over a period of 6 to 12 months and reflect the analyst s view of the potential for change in stock price as a percentage. The BUY and SELL ratings reflect the analyst s expected high change in the value of the stock. The levels of change expressed in each rating categories are: BUY > +10% HOLD <=-10% and < = +10% SELL > -10%. Analyst certification I, Ralf Marinoni, financial analyst, hereby certifies that all of the views expressed in this report accurately reflect my personal views about any and all of the subject securities or issuers discussed herein. In addition, I hereby certify that no part of my compensation was, is, or will be, directly or indirectly related to the specific recommendations or views expressed in this research report, nor is it tied to any specific investment banking transaction performed by the Bank or its affiliates. Price and Rating History (last 12 months) EQS Group AG Date Price target-eur Rating Initiation 18.05.2017 60.00 Buy 18.11.2016 50.00 Buy 07.10.2016 50.00 Buy 07.10.2016 Bank distribution of ratings and in proportion to investment banking services can be found on the internet at the following address: http://investment-banking.quirinbank.de/institutional-research Competent supervisory authority Bundesanstalt für Finanzdienstleistungsaufsicht - BaFin (Federal Financial Supervisory Authority), Graurheindorfer Str. 108, 53117 Bonn Contact Quirin Privatbank AG Frankfurt am Main Schillerhaus / Schillerstraße 20 / 60313 Frankfurt am Main Management Board: Karl Matthäus Schmidt Johannes Eismann Monday, August 14, 2017 3

Contact Details Quirin Privatbank AG Schillerhaus Schillerstrasse 20 60313 Frankfurt am Main : +49 69 2 47 50 49-0 Fax: +49 69 2 47 50 49-44 Institutional-Sales-FFM@quirinprivatbank.de Research Klaus Soer +49 (0) 69 2475049-27 klaus.soer@quirinprivatbank.de Ralf Marinoni +49 (0) 69 2475049-24 ralf.marinoni@quirinprivatbank.de Institutional Sales Bruno de Lencquesaing +49 (0) 69 2475049-81 bruno.delencquesaing@quirinprivatbank.de Rüdiger Eich +49 (0) 69 2475049-85 ruediger.eich@quirinprivatbank.de Sule Erkan +49 (0) 69 2475049-88 sule.erkan@quirinprivatbank.de Rainer Jell +49 (0) 69 2475049-45 rainer.jell@quirinprivatbank.de Stefan Krewinkel +49 (0) 69 2475049-43 stefan.krewinkel@quirinprivatbank.de Klaus Linnebach +49 (0) 69 2475049-47 klaus.linnebach@quirinprivatbank.de Klaus Messenzehl +49 (0) 69 2475049-46 klaus.messenzehl@quirinprivatbank.de Jürgen Raabe +49 (0) 69 2475049-41 juergen.raabe@quirinprivatbank.de Janine Theobald +49 (0) 69 2475049-83 janine.theobald@quirinprivatbank.de Sales Trading Thomas Flügel +49 (0) 69 2475049-92 thomas.fluegel@quirinprivatbank.de Jean-Marie Frémion +49 (0) 69 2475049-90 jean-marie.fremion@quirinprivatbank.de Peter Rumstich +49 (0) 69 2475049-65 peter.rumstich@quirinprivatbank.de Monday, August 14, 2017 4

Monday, August 14, 2017 5